Shire (SHP.L) reported a fall in third-quarter sales of hemophilia drugs acquired in its $32 billion Baxalta deal in June, resulting in a rare miss on both the top and bottom lines and sending its shares lower.
Sales of Baxalta’s hematology products fell by 6 percent to $884 million, Shire said, adding that the number was hit by the timing of large orders outside the United States.
Source: Reuters
Filed Under: Drug Discovery